ClinicalTrials.gg
CompletedNCT05399680RADIANCYUpdated Aug 11, 2025Results posted

Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access

An interventional study of S.M.A.R.T. RADIANZ™ Vascular Stent System and BRITE TIP RADIANZ™ Guiding Sheath in Peripheral Arterial Disease, sponsored by Cordis US Corp.. Completed at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Cordis US Corp. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Peripheral Arterial Disease with a site in Austria — 7 open to participants now, 16 under way, 2 of them phase 3. Peripheral Arterial Disease · Austria.

Enrollment
30th of 58
151 · median 170
Started
2022
with 9 others
No phase
41 of 74
3 open now
Registered
62nd of 74
by date

Among the 74 studies in Peripheral Arterial Disease with a site in Austria, this one is the 30th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2022, is one of 41 with no phase, and was the 62nd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 74 studies in Peripheral Arterial Disease with a site in Austria are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Peripheral Arterial Disease with a site in Austria, or all of them as a file.
02

Study summary

The primary objective of this clinical investigation was to evaluate acute safety and efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System, when used with the BRITE TIP RADIANZ™ Guiding Sheath and SABERX RADIANZ™ PTA Balloon Catheter, to deploy the S.M.A.R.T.™ Nitinol Stent, in the treatment of patients with obstructive iliac or femoropopliteal arterial disease via radial artery access.

Read the detailed description

RADIANCY was an acute, multi-center, single-arm, non-randomized, prospective, pivotal (pre-market) clinical study, whose primary objective was to evaluate acute safety and efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System, when used with the BRITE TIP RADIANZ™ Guiding Sheath and SABERX RADIANZ™ PTA Balloon Catheter, to deploy the S.M.A.R.T.™ self-expanding stent in the treatment of patients with obstructive iliac or femoropopliteal arterial disease via transradial artery access. The study enrolled 151 subjects, 22 of which were enrolled as "roll-in" subjects, at 12 investigational sites across Europe. These subjects were followed up to 30 days post-procedure.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the following inclusion criteria to be enrolled in the study:

ALL patients must meet the following criteria prior to enrollment:

  1. Age ≥ 18 years
  2. For women of , a negative pregnancy test within seven (7) days prior to the index procedure
  3. Symptomatic leg ischemia or ischemic ulcerations that do NOT exceed digits of the foot (Rutherford/Becker Classification category 2, 3, 4 or 5)
  4. Palpable radial artery with diameter ≥ 2.5 mm, as assessed by duplex ultrasound
  5. Eligibility for standard surgical repair, if necessary
  6. A patient who requires a coronary intervention should have it performed at least seven (7) days prior to treatment of the target lesion
  7. The patient must provide documented and any other documented authorization, as required, prior to initiation of the study procedure
  8. Per Investigator assessment, the patient is willing and able to be followed up to 30 days post-procedure for evaluation and complete all required assessments per the study protocol.

    Inclusion criteria 9 and 10 AND 11a through 14a OR 11b through 16b (whichever is applicable) would be assessed via baseline angiography performed at the time of index procedure:

  9. The Investigator has assessed that the patient is a suitable candidate (i.e, meets all inclusion criteria and none of the exclusion criteria), for treatment of a lesion in the iliac, superficial femoral and/or proximal popliteal arteries via transradial approach and is eligible for conversion from a transradial to transfemoral approach, if it becomes necessary.
  10. The guidewire is across the target lesion(s) and located intraluminally within the distal vessel following a transradial approach

Patients whose target lesion is in the iliac artery must meet these additional criteria prior to enrollment:

11a. A single de novo or restenotic lesion ≥ 50% stenosis in the common and/or external iliac artery

12a. Stenotic lesion (one long or multiple serial/tandem lesions) less than or equal to 100 mm, by visual assessment, within or across the common or external iliac arteries. The stenosis must be treatable with no more than two stents (while minimizing stent overlap)

13a. Reference vessel diameter (RVD) ranging from 4.0 to 9.0 mm by visual assessment

14a. Angiographic evidence of a patent profunda or superficial femoral artery in the diseased (target) limb

Patients whose target lesion is in the SFA and/or PPA must meet these additional criteria prior to enrollment:

11b. A single de novo or restenotic lesion ≥ 50% stenosis in the SFA and/or PPA

12b. Stenotic lesion (one long or multiple serial/tandem lesions) less than or equal to 150 mm, by visual assessment, within or across the SFA and/or PPA. The stenosis must be treatable with no more than two stents (while minimizing stent overlap)

13b. RVD ranging from 4.0 to 7.0 mm by visual assessment

14b. All lesions are to be located at least three centimeters proximal to the superior edge of the patella

15b. Patent infrapopliteal artery, i.e., single vessel runoff or better with patency (\<50% stenosis) of at least one of three vessels to the ankle or foot

16b. Adequate aortoiliac or common femoral "inflow" (defined as \< 30% stenosis after PTA or stenting) prior to treatment of the target lesion (defined as \< 30% stenosis after PTA or stenting) prior to treatment of the target lesion

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if ANY of the following exclusion criteria apply:

  1. The patient has had/experienced any prior intervention/treatment to the target vessel within 90 days prior to enrollment (e.g., previously implanted graft in the aorta or target vessel; stroke; cryoplasty, laser or atherectomy; abdominal aortic aneurysm or aneurysm of the iliac, superficial femoral or popliteal artery).
  2. Previously deployed stent at the site of the target lesion
  3. The patient has post-surgical stenosis and anastomotic suture treatments of the target vessel
  4. Requires general anesthesia for percutaneous transluminal angioplasty (PTA) and/or the stenting procedure
  5. Use of mechanical devices on or thrombolysis of the target vessel within 72 hours prior to the index procedure without complete resolution of the thrombus
  6. The patient is receiving any form of dialysis.
  7. The patient is receiving any form of therapy.
  8. Planned amputation
  9. Established vasospastic disease
  10. (GFR) \< 30 mL/min within 7 days prior to the index procedure
  11. The patient has a history of neutropenia, coagulopathy, and/or thrombocytopenia.
  12. Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days prior to the index procedure
  13. Bleeding diathesis
  14. Known allergies or intolerance to antiplatelet, anticoagulant or thrombolytic medications including but not limited to aspirin, clopidogrel bisulfate (Plavix®), ticlopidine (Ticlid®) or heparin that cannot be medically managed.
  15. Known allergy or intolerance to Nitinol (nickel titanium)
  16. Known allergy to contrast agent that cannot be medically managed before treatment with and/or antihistamines.
  17. Known or suspected active infection at the time of the index procedure.
  18. Patient is currently participating in another drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or is planning to participate in such a study prior to their completion of this study.
  19. Patient has had a major surgical or interventional procedure unrelated to this study within 30 days prior to enrollment or is anticipated/planned to have such a procedure within 30 days after enrollment.

    Exclusion criteria 20 through 25 would be assessed via baseline angiography performed at the time of index procedure:

  20. Significant vessel tortuosity or other parameters prohibiting access to the lesion or 90° tortuosity which would prevent delivery of the stent device
  21. Noted perforation of the target vessel
  22. Stent placement required across or within 0.5 cm of the SFA/profunda femoris artery (PFA) bifurcation
  23. Cases of chronic total occlusion/in-stent restenosis/severe calcification in which there is pre-determined inability to treat the target lesion with a single stent, or procedures pre-determined to require stent-in-stent placement to obtain patency
  24. Presence of thrombus prior to crossing the lesion
  25. Successful PTA treatment of a target lesion in the SFA/PPA (defined as \< 50% stenosis after PTA treatment)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Interventional

    Treatment with SMART RADIANZ, BRITE TIP RADIANZ and SABERX RADIANZ devices

    Device: S.M.A.R.T. RADIANZ™ Vascular Stent System · Device: BRITE TIP RADIANZ™ Guiding Sheath · Device: SABERX RADIANZ™ PTA Balloon Catheter

Interventions

  • DeviceS.M.A.R.T. RADIANZ™ Vascular Stent System

    The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.

  • DeviceBRITE TIP RADIANZ™ Guiding Sheath

    BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.

  • DeviceSABERX RADIANZ™ PTA Balloon Catheter

    SABERX RADIANZ™ is a catheter with a distal inflatable balloon.

06

What researchers measure

Primary outcomes

  1. Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome)

    Occurrence rate of CEC-adjudicated, major radial access site complications attributed to study device or procedure through time of hospital discharge.

    Time frame: From the time of sheath introduction through the radial artery (start time of procedure) through time of discharge (within ~48 hours of end time of procedure) or study exit, whichever comes first

  2. Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome)

    Technical success at the conclusion of the index procedure, defined as successful insertion of the S.M.A.R.T. RADIANZ™ Vascular Stent System into the peripheral vasculature through the radial artery, successful deployment of the study device (S.M.A.R.T.™ stent) at the intended location, and successful withdrawal of the delivery system without conversion from radial to femoral artery access.

    Time frame: From the time of insertion to the time of withdrawal of the SMART RADIANZ Vascular Stent System through the radial access artery, within the same day or 24 hours from the procedure start time

Secondary outcomes

  1. Device Deficiencies Through 30 Days Post-Procedure

    For each of the three (3) devices, peri-procedural (within 30 days post-index procedure) rate of device deficiencies

    Time frame: From the time of first use/handling of the device to 30 days from date of index procedure or study exit, whichever comes first

  2. Adverse Events Through 30 Days Post-Procedure

    Peri-procedural (within 30 days post-index procedure) rate of adverse events

    Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first

  3. Death, Index Limb Amputation and TLR Through 30 Days Post-Procedure

    Peri-procedural (within 30 days post-index procedure) rate of death, index limb amputation and target lesion revascularization

    Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first

  4. Procedural Complications Through 30 Days Post-Procedure

    Peri-procedural (within 30 days post-index procedure) rate of procedural complications

    Time frame: From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first

  5. Technical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath

    Technical success associated with use of the BRITE TIP RADIANZ™ Guiding Sheath, defined as successful insertion of the device into the peripheral vasculature through the radial artery (allowing for introduction of interventional and/or diagnostic devices) and successful withdrawal of the device.

    Time frame: From the time of insertion through the time of withdrawal of the BRITE TIP RADIANZ™ Guiding Sheath through the radial access artery, assessed within the same day or 24 hours from the start time of the index procedure.

  6. Procedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter

    Procedural success associated with use of the SABERX RADIANZ™ PTA Balloon Catheter for pre-dilation and/or post-deployment stent dilatation (whenever applicable), defined as successful insertion of the device into the peripheral vasculature through the radial artery, successful inflation and deflation of the balloon, successful withdrawal of the device, and achievement of a final residual diameter stenosis of \< 30% at the conclusion of the index procedure.

    Time frame: From the time of insertion to the time of withdrawal of the SABERX RADIANZ™ PTA Balloon Catheter through the radial access artery AND assessment of the final residual diameter stenosis, within the same day or 24 hours from the procedure start time

Other outcomes

  1. Fluoroscopy Time

    Fluoroscopy time is the length of time during which X-rays are produced during a fluoroscopy procedure.

    Time frame: From the start time to the end time of the period during which x-rays are produced, within the same day or 24 hours from the procedure start time

  2. Time to Achieve Hemostasis

    Time to achieve hemostasis defined as the time elapsed from removal of the BRITE TIP RADIANZTM Guiding Sheath to the time that hemostasis was first observed.

    Time frame: From the time of removal of the BRITE TIP RADIANZ Guiding Sheath to when hemostasis was first observed, within the same day or 24 hours from the procedure start time

  3. Time to Ambulation

    Time to ambulation, defined as the time from when vascular closure was achieved to when the subject could stand up and walk any distance

    Time frame: From the time of vascular closure to the time of ambulation, within the same day or 24 hours from the procedure start time, or study exit, whichever comes first

  4. Time to Hospital Discharge

    Time to hospital discharge

    Time frame: From the time of vascular closure to the time of hospital discharge (~ up to 1 week from date of index procedure) or study exit, whichever comes first

  5. Method to Achieve Closure of the Transradial Artery Access Site

    Method to achieve closure of the transradial artery access site

    Time frame: From the time of removing the BRITE TIP RADIANZ Guiding Sheath to the time of either removing the vascular closure device or ending manual compression, within the same day or 24 hours from the procedure start time

  6. Quality of Life Assessed Via the SF-36 Questionnaires - General Health

    Mean scores are reported on a scale entitled "mean score" and range from 0 (minimum) to 100 (maximum); higher scores represent a better outcome.

    Time frame: Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)

  7. Quality of Life Assessed Via the EuroQOL-5 Dimensions (EQ-5D) Questionnaire - Overall Health

    The EQ-5D questionnaire is an instrument designed to assess quality of life along five (5) dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each participant, a value-based scoring system is used to convert the combination of their responses to the five individual subscales into a single index value (or a code), which is then converted into a single score based on how people in the participant's country rate different combinations of problems. The EQ-5D score for Overall Health is reported as a mean and standard deviation at screening, discharge and 30 days in this module and ranges from 0 (minimum) to 100 (maximum) with higher scores representing better outcomes.

    Time frame: Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)

  8. Time to Hospital Discharge Eligibility

    Time to hospital discharge eligibility (when physician examines and if all is well, gives discharge orders)

    Time frame: From the time of vascular closure to the time of hospital discharge eligibility (~ up to 1 week from date of index procedure) or study exit, whichever comes first

  9. Procedural Time

    Procedural Time is defined as the time elapsed from when the sheath was introduced through the radial access artery to the time of vascular closure.

    Time frame: From the time of introduction of the sheath through the radial access artery to the time of vascular closure, within the same day or 24 hours from the procedure start time

07

Results

Posted Aug 11, 2025
Limitations and caveats
The cohort investigated excluded patients with various, pre-existing conditions and comorbidities, and so experienced clinicians should carefully consider in whom they prescribe intervention with the S.M.A.R.T. RADIANZ™ Vascular Stent System. Future studies could be undertaken to better ascertain the PAD patient cohorts that most likely stand to benefit from specifically from radial access and the S.M.A.R.T. RADIANZ™ Vascular Stent System compared to other contemporary treatment approaches.

Participant flow

A total of 151 enrolled subjects were enrolled between June 29, 2022 and September 22, 2023 at 12 institutions/hospitals across 6 European countries.

Participant flow — Overall Study
MilestoneMain CohortRoll-in Cohort
Started12922
Completed12821
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Death01

Outcome measures

PrimaryOccurrence Rate of Radial Access Site Complications (Primary Safety Outcome)

Occurrence rate of CEC-adjudicated, major radial access site complications attributed to study device or procedure through time of hospital discharge.

Time frame:
From the time of sheath introduction through the radial artery (start time of procedure) through time of discharge (within ~48 hours of end time of procedure) or study exit, whichever comes first
Reported as:
Count of participants · Participants
Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome)
ParticipantsInterventional
Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome)0
PrimaryTechnical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome)

Technical success at the conclusion of the index procedure, defined as successful insertion of the S.M.A.R.T. RADIANZ™ Vascular Stent System into the peripheral vasculature through the radial artery, successful deployment of the study device (S.M.A.R.T.™ stent) at the intended location, and successful withdrawal of the delivery system without conversion from radial to femoral artery access.

Time frame:
From the time of insertion to the time of withdrawal of the SMART RADIANZ Vascular Stent System through the radial access artery, within the same day or 24 hours from the procedure start time
Reported as:
Count of participants · Participants
Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome)
ParticipantsInterventional
Technical Success of Using the S.M.A.R.T. RADIANZ™ Vascular Stent System (Primary Efficacy Outcome)122
SecondaryDevice Deficiencies Through 30 Days Post-Procedure

For each of the three (3) devices, peri-procedural (within 30 days post-index procedure) rate of device deficiencies

Time frame:
From the time of first use/handling of the device to 30 days from date of index procedure or study exit, whichever comes first
Reported as:
Count of participants · Participants
Device Deficiencies Through 30 Days Post-Procedure
ParticipantsInterventional
BRITE TIP RADIANZ1
SMART RADIANZ1
SABERX RADIANZ0
SecondaryAdverse Events Through 30 Days Post-Procedure

Peri-procedural (within 30 days post-index procedure) rate of adverse events

Time frame:
From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Reported as:
Count of participants · Participants
Adverse Events Through 30 Days Post-Procedure
ParticipantsInterventional
Adverse Events Through 30 Days Post-Procedure24
SecondaryDeath, Index Limb Amputation and TLR Through 30 Days Post-Procedure

Peri-procedural (within 30 days post-index procedure) rate of death, index limb amputation and target lesion revascularization

Time frame:
From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Reported as:
Count of participants · Participants
Death, Index Limb Amputation and TLR Through 30 Days Post-Procedure
ParticipantsInterventional
Death0
Index Limb Amputation1
Target Lesion Revascularization0
SecondaryProcedural Complications Through 30 Days Post-Procedure

Peri-procedural (within 30 days post-index procedure) rate of procedural complications

Time frame:
From the time of introduction of the sheath through the radial access artery to 30 days from date of index procedure or study exit, whichever comes first
Reported as:
Count of participants · Participants
Procedural Complications Through 30 Days Post-Procedure
ParticipantsInterventional
No Conversion from Radial Artery128
BRITE TIP RADIANZ Insertion129
Guidewire Across Target Lesion129
SABERX RADIANZ Insertion128
Balloon Inflation113
S.M.A.R.T. RADIANZ Insertion123
Stent Deployed117
SecondaryTechnical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath

Technical success associated with use of the BRITE TIP RADIANZ™ Guiding Sheath, defined as successful insertion of the device into the peripheral vasculature through the radial artery (allowing for introduction of interventional and/or diagnostic devices) and successful withdrawal of the device.

Time frame:
From the time of insertion through the time of withdrawal of the BRITE TIP RADIANZ™ Guiding Sheath through the radial access artery, assessed within the same day or 24 hours from the start time of the index procedure.
Reported as:
Count of participants · Participants
Technical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath
ParticipantsInterventional
Technical Success of Using the BRITE TIP RADIANZ™ Guiding Sheath129
SecondaryProcedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter

Procedural success associated with use of the SABERX RADIANZ™ PTA Balloon Catheter for pre-dilation and/or post-deployment stent dilatation (whenever applicable), defined as successful insertion of the device into the peripheral vasculature through the radial artery, successful inflation and deflation of the balloon, successful withdrawal of the device, and achievement of a final residual diameter stenosis of \< 30% at the conclusion of the index procedure.

Time frame:
From the time of insertion to the time of withdrawal of the SABERX RADIANZ™ PTA Balloon Catheter through the radial access artery AND assessment of the final residual diameter stenosis, within the same day or 24 hours from the procedure start time
Reported as:
Count of participants · Participants
Procedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter
ParticipantsInterventional
Procedural Success of Using the SABERX RADIANZ™ PTA Balloon Catheter79
Other pre-specifiedFluoroscopy Time

Fluoroscopy time is the length of time during which X-rays are produced during a fluoroscopy procedure.

Time frame:
From the start time to the end time of the period during which x-rays are produced, within the same day or 24 hours from the procedure start time
Reported as:
Mean · minutes
Fluoroscopy Time
minutesInterventional
Fluoroscopy Time9 ± 4
Other pre-specifiedTime to Achieve Hemostasis

Time to achieve hemostasis defined as the time elapsed from removal of the BRITE TIP RADIANZTM Guiding Sheath to the time that hemostasis was first observed.

Time frame:
From the time of removal of the BRITE TIP RADIANZ Guiding Sheath to when hemostasis was first observed, within the same day or 24 hours from the procedure start time
Reported as:
Mean · minutes
Time to Achieve Hemostasis
minutesInterventional
Time to Achieve Hemostasis47 ± 20
Other pre-specifiedTime to Ambulation

Time to ambulation, defined as the time from when vascular closure was achieved to when the subject could stand up and walk any distance

Time frame:
From the time of vascular closure to the time of ambulation, within the same day or 24 hours from the procedure start time, or study exit, whichever comes first
Reported as:
Mean · minutes
Time to Ambulation
minutesInterventional
Time to Ambulation207 ± 153
Other pre-specifiedTime to Hospital Discharge

Time to hospital discharge

Time frame:
From the time of vascular closure to the time of hospital discharge (~ up to 1 week from date of index procedure) or study exit, whichever comes first
Reported as:
Mean · hours
Time to Hospital Discharge
hoursInterventional
Time to Hospital Discharge15.6 ± 9.5
Other pre-specifiedMethod to Achieve Closure of the Transradial Artery Access Site

Method to achieve closure of the transradial artery access site

Time frame:
From the time of removing the BRITE TIP RADIANZ Guiding Sheath to the time of either removing the vascular closure device or ending manual compression, within the same day or 24 hours from the procedure start time
Reported as:
Count of participants · Participants
Method to Achieve Closure of the Transradial Artery Access Site
ParticipantsInterventional
Manual Compression2
Radial Compression Band127
Other pre-specifiedQuality of Life Assessed Via the SF-36 Questionnaires - General Health

Mean scores are reported on a scale entitled "mean score" and range from 0 (minimum) to 100 (maximum); higher scores represent a better outcome.

Time frame:
Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)
Reported as:
Mean · score on a scale
Quality of Life Assessed Via the SF-36 Questionnaires - General Health
score on a scaleInterventional
Screening47.56 ± 17.67
Discharge52.44 ± 15.10
30 Day Follow-Up60.71 ± 16.43
Other pre-specifiedQuality of Life Assessed Via the EuroQOL-5 Dimensions (EQ-5D) Questionnaire - Overall Health

The EQ-5D questionnaire is an instrument designed to assess quality of life along five (5) dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each participant, a value-based scoring system is used to convert the combination of their responses to the five individual subscales into a single index value (or a code), which is then converted into a single score based on how people in the participant's country rate different combinations of problems. The EQ-5D score for Overall Health is reported as a mean and standard deviation at screening, discharge and 30 days in this module and ranges from 0 (minimum) to 100 (maximum) with higher scores representing better outcomes.

Time frame:
Screening is up to 7 days prior to the index procedure date; discharge is between end of index procedure and 7 days post-discharge; the 30-day follow-up visit is between 23 and 37 days post-procedure, or until time of study exit (whichever comes first)
Reported as:
Mean · score on a scale
Quality of Life Assessed Via the EuroQOL-5 Dimensions (EQ-5D) Questionnaire - Overall Health
score on a scaleInterventional
Screening63.20 ± 16.24
Discharge70.66 ± 14.08
30 Day78.01 ± 13.95
Other pre-specifiedTime to Hospital Discharge Eligibility

Time to hospital discharge eligibility (when physician examines and if all is well, gives discharge orders)

Time frame:
From the time of vascular closure to the time of hospital discharge eligibility (~ up to 1 week from date of index procedure) or study exit, whichever comes first
Reported as:
Mean · hours
Time to Hospital Discharge Eligibility
hoursInterventional
Time to Hospital Discharge Eligibility14.3 ± 10.1
Other pre-specifiedProcedural Time

Procedural Time is defined as the time elapsed from when the sheath was introduced through the radial access artery to the time of vascular closure.

Time frame:
From the time of introduction of the sheath through the radial access artery to the time of vascular closure, within the same day or 24 hours from the procedure start time
Reported as:
Mean · minutes
Procedural Time
minutesInterventional
Procedural Time47 ± 20

Adverse events

Collected over Peri-procedural (within 30 days post-index procedure). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Cohort0/129 (0%)5/129 (3.9%)10/129 (7.8%)
Roll-in Cohort1/22 (4.5%)6/22 (27.3%)0/22 (0%)
Most frequent serious events
Most frequent serious events
EventMain CohortRoll-in Cohort
Acute myocardial infarctionCardiac disorders0/1292/22
Iliac artery perforationCardiac disorders0/1291/22
UlcerGeneral disorders0/1291/22
Wound complicationInjury, poisoning and procedural complications0/1291/22
Haemoglobin decreasedInvestigations0/1291/22
Rectal hemorrhageGastrointestinal disorders1/1290/22
Arterial injuryInjury, poisoning and procedural complications1/1290/22
Cerebrovascular accidentNervous system disorders1/1290/22
Skin necrosisSkin and subcutaneous tissue disorders1/1290/22
IschaemiaVascular disorders1/1290/22
Most frequent other events
Most frequent other events
EventMain CohortRoll-in Cohort
Vascular access site haematomaGeneral disorders10/1290/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Main CohortRoll-in CohortTotal
Mean68.23 ± 9.4468.45 ± 8.9068.26 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)Main CohortRoll-in CohortTotal
Female34337
Male9519114
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Main CohortRoll-in CohortTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Main CohortRoll-in CohortTotal
Austria43851
Italy17219
France65873
Spain426
Switzerland011
Belgium011
Medical History
Medical History(Participants)Main CohortRoll-in CohortTotal
COPD15419
Chronic Renal Failure448
Diabetes Mellitus39544
Heart Failure617
Hypercholesterolemia9316109
Hypertension9819117
Peripheral Artery Disease9615111
Previous Cerebrovascular Accident718
Previous Myocardial Infarction9110
Smoking9118109
Smoking Unknown314
Physical Examination Condition
Physical Examination Condition(Participants)Main CohortRoll-in CohortTotal
Peripheral Artery Disease Symptoms12921150
Claudication Symptoms12720147
Muscle Plain with Exercise11017127
Critical Limb Symptoms12315
Pain at Rest13114
Height (cm)
Height (cm)(centimeters)Main CohortRoll-in CohortTotal
Mean170.48 ± 8.30172.5 ± 9.02170.77 ± 8.41
Weight (kg)
Weight (kg)(kg)Main CohortRoll-in CohortTotal
Mean77.01 ± 14.3382.78 ± 15.4277.85 ± 14.59

6 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Univ Klinikum LKG Graz
    Graz, Austria
  • Klinikum Klagenfurt am Wörtherse
    Klagenfurt, Austria
  • Hanusch Krankenhaus
    Vienna, Austria
  • Univ.-Klinik für Innere Medizin II
    Vienna, Austria
  • A.Z. Sint-Blasius Hospital-Dendermonde
    Dendermonde, Belgium
  • Hospital Ambroise Pare
    Boulogne-Billancourt, France
  • Groupe Hôpital Paris St Joseph
    Paris, France
  • Clinique Rhena
    Strasbourg, France
  • Clinique Pasteur
    Toulouse, France
  • Maria Cecilia Hospital
    Cotignola, Italy
  • Hosp Univ. de Guadalajara
    Guadalajara, Spain
  • Kantonsspital Winterthur
    Winterthur, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2023, 14 months.

Results were first posted in Aug 2025, 1 year 10 months after primary completion.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Jun 1, 2022
StartActual
Jun 29, 2022
Primary completionActual
Sep 22, 2023
CompletionActual
Nov 13, 2023
Results first posted
Aug 11, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05399680
Lead sponsor
Cordis US Corp.
Collaborators
Qserve, NAMSA
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Jun 29, 2022
Primary completion
Sep 22, 2023
Completion
Nov 13, 2023
Results posted
Aug 11, 2025
Last update
Aug 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion